Remogliflozin etabonate

Remogliflozin etabonate is an antidiabetic drug in the SGLT2 inhibitors class. It was developed by BHV Pharma and is currently marketed in India by Glenmark Pharmaceuticals under the brand name Sugalpha ER.

Medical uses

Remogliflozin etabonate is used in the treatment of Type 2 diabetes. It works by inhibiting the SGLT2 protein, which is involved in glucose reabsorption in the kidneys. This leads to an increase in glucose excretion and a decrease in blood glucose levels.

Side effects

The most common side effects of remogliflozin etabonate include urinary tract infections, genital infections, and increased urination. Less common side effects may include low blood pressure, ketoacidosis, and kidney injury.

Pharmacology

Remogliflozin etabonate is a prodrug that is metabolized in the body to its active form, remogliflozin. It inhibits the SGLT2 protein in the proximal tubules of the kidneys, leading to an increase in glucose excretion and a decrease in blood glucose levels.

History

Remogliflozin etabonate was developed by BHV Pharma and is currently marketed in India by Glenmark Pharmaceuticals. It was approved for use in India in April 2019.

See also

• List of SGLT2 inhibitors
• Diabetes management

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  Remogliflozin etabonate structure